GALNT3 and thyroid cancer, nonmedullary, 2: The parents of the patients in our study carried compound heterozygotes for the two mutations in exon 2, which were reported in 11 of 32 families with FTC or hyperostosis-hyperphosphatemia syndrome caused by GALNT3 mutations (Table 2), but they were reluctant to participate in additional examinations to exclude mild FTC or hyperostosis-hyperphosphatemia syndrome.